CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015
- Data supports prolonged dosing intervals up to 14 days for routine prophylaxis in hemophilia B patients - Majority of adult and pediatric patients using rIX-FP for routine prophylaxis had an annualized spontaneous bleeding rate (AsBR) of 0.00 - Surgical sub study results show single dose of rIX-FP sufficient to maintain hemostasis during surgery TORONTO, June 24, 2015 /PRNewswire/ --